Burden of herpes zoster in the UK: Findings from the zoster quality of life (ZQOL) study

BMC Infectious Diseases

Volumn 14, Issue 1, 2014, Pages

  Gater, Adam ^a   Abetz Webb, Linda ^a   Carroll, Stuart ^b   Mannan, Azharul ^b   Serpell, Mick ^c   Johnson, Robert ^d  

^a ADELPHI REAL WORLD   (United Kingdom)

^b Sanofi Pasteur MSD   (United Kingdom)

^c GARTNAVEL GENERAL HOSPITAL   (United Kingdom)

^d UNIVERSITY OF BRISTOL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ACICLOVIR; ANALGESIC AGENT; ANTIVIRUS AGENT;

ABSENTEEISM; ADULT; AGED; ARTICLE; CONTROLLED STUDY; CROSS-SECTIONAL STUDY; EUROQOL 5 DIMENSIONS; FEMALE; HEALTH CARE UTILIZATION; HERPES ZOSTER; HUMAN; MAJOR CLINICAL STUDY; MALE; OBSERVATIONAL STUDY; PAIN; PATIENT SATISFACTION; QUALITY OF LIFE; QUESTIONNAIRE; RASH; SHORT FORM 36; TREATMENT SATISFACTION WITH MEDICATION QUESTIONNAIRE; UNITED KINGDOM; WELLBEING; ZOSTER BRIEF PAIN INVENTORY; DISEASE ASSOCIATION; DISEASE SEVERITY; DRUG SAFETY; ECONOMIC ASPECT; ECONOMIC BURDEN; EUROQOL 5 DIMENSION; FOLLOW UP; NEURALGIA; OUTCOME ASSESSMENT; PAIN ASSESSMENT; PHYSICAL CAPACITY; PSYCHOLOGICAL WELL BEING;

AGED; ANALGESICS; CROSS-SECTIONAL STUDIES; DATA COLLECTION; FEMALE; GREAT BRITAIN; HERPES ZOSTER; HUMANS; MALE; MIDDLE AGED; PAIN; QUALITY OF LIFE; QUESTIONNAIRES;

EID: 84904448103     PISSN: None     EISSN: 14712334     Source Type: Journal    
DOI: 10.1186/1471-2334-14-402     Document Type: Article

References (55)

1. Cohen J, Powderly WG, Berkley SF, Calandra T, Clumeck N, Finch RG. Infectious Diseases 2003, London: Mosby, 2.
2. Schmader K, Gnann JW, Watson CP. The Epidemiological, Clinical, and Pathological Rationale for the Herpes Zoster Vaccine. J Infect Dis 2008, 197:S207-S215.
3. Johnson RW, Wasner G, Saddier P, Baron R. Postherpetic neuralgia: epidemiology, pathophysiology and management. Expert Rev Neurother 2007, 7:1581-1595.
4. Dworkin RH, Schmader KE. The epidemiology and natural history of herpes zoster and postherpetic neuralgia. Herpes Zoster and Postherpetic Neuralgia 2001, 39-64. Amsterdam: Elsevier, 2.
5. Drolet M, Brisson M, Schmader KE, Levin MJ, Johnson R, Oxman MN, Patrick D, Blanchette C, Mansi JA. The impact of herpes zoster and postherpetic neuralgia on health-related quality of life: a prospective study. Can Med Assoc J 2010, 182:1731-1736.
6. Schmader KE, Sloane R, Pieper C, Coplan PM, Nikas A, Saddier P, Chan ISF, Choo P, Levin MJ, Johnson G, Williams HM, Oxman MN. The impact of acute herpes zoster pain and discomfort on functional status and quality of life in older adults. Clin J Pain 2007, 23:490-496.
7. van Seventer R, Sadosky A, Lucero M, Dukes E. A cross-sectional survey of health state impairment and treatment patterns in patients with postherpetic neuralgia. Age Ageing 2006, 35:132-137.
8. Scott FT, Johnson RW, Leedham-Green M, Davies E, Edmunds WJ, Breuer J. The burden of Herpes Zoster: a prospective population based study. Vaccine 2006, 24:1308-1314.
9. Oster G, Harding G, Dukes E, Edelsberg J, Cleary PD. Pain, medication use, and health-related quality of life in older persons with postherpetic neuralgia: results from a population-based survey. J Pain 2005, 6:356-363.
10. Katz J, Cooper EM, Walther RR, Sweeney EW, Dworkin RH. Acute pain in herpes zoster and its impact on health-related quality of life. Clin Infect Dis 2004, 39:342-348.
11. Chidiac C, Bruxelle J, Daures JP, Hoang-Xuan T, Morel P, Leplege A, El Hasnaoui A, de Labareyre C. Characteristics of patients with herpes zoster on presentation to practitioners in France. Pain Pract 2001, 1:381.
12. Gauthier A, Breuer J, Carrington D, Martin M, Remy V. Epidemiology and cost of herpes zoster and post-herpetic neuralgia in the United Kingdom. Epidemiol Infect 2009, 137:38-47.
13. Rothberg MB, Virapongse A, Smith KJ. Cost-effectiveness of a vaccine to prevent herpes zoster and postherpetic neuralgia in older adults. Clin Infect Dis 2007, 44:1280-1288.
14. Dworkin RH, White R, O'Connor AB, Baser O, Hawkins K. Healthcare costs of acute and chronic pain associated with a diagnosis of herpes zoster. J Am Geriatr Soc 2007, 55:1168-1175.
15. Yawn BP, Itzler RF, Wollan PC, Pellissier JM, Sy LS, Saddier P. Health care utilization and cost burden of herpes zoster in a community population. Mayo Clin Proc 2009, 84:787-794.
16. Insinga RP, Itzler RF, Pellissier JM. Acute/subacute herpes zoster: healthcare resource utilisation and costs in a group of US health plans. Pharmacoeconomics 2007, 25:155-169.
17. Brisson M, Pellissier JM, Camden S, Quach C, De WP. The potential cost-effectiveness of vaccination against herpes zoster and post-herpetic neuralgia. Hum Vaccin 2008, 4:238-245.
18. Joint Committee on Vaccination and Immunisation Minutes of the Meeting held on 14 October 2009 2009, London: JCVI, Joint Committee on Vaccination and Immunisation.
19. Joint Committee on Vaccination and Immunisation Varicellar Subgroup Minutes of the Varicella JCVI Subgroup Meeting on Monday 9th March 2009 2009, London: JCVI, Joint Committee on Vaccination and Immunisation Varicellar Subgroup.
20. Serpell M, Gater A, Abetz-Webb L, Carroll S, Mannan A, Johnson RW. Burden of Post-Herpetic Neuralgia in a sample of UK residents aged 50 years or older: Findings from the Zoster Quality of Life (ZQOL) Study. Health Qual Life Outcome 2014, 12:92.
21. Hochberg Y. A sharper Bonferroni procedure for multiple tests of significance. Biometrika 1988, 75:800-802.
22. Lancaster T, Silagy C, Gray S. Primary care management of acute herpes zoster: systematic review of evidence from randomized controlled trials. Br J Gen Pract 1995, 45:39-45.
23. Lydick E, Epstein RS, Himmelberger D, White CJ. Herpes zoster and quality of life: a self-limited disease with severe impact. Neurology 1995, 45:S52-S53.
24. Coplan PM, Schmader K, Nikas A, Chan IS, Choo P, Levin MJ. Development of a measure of the burden of pain due to herpes zoster and postherpetic neuralgia for prevention trials: adaptation of the brief pain inventory. J Pain 2004, 5:344-356.
25. Cleeland CS, Gonin R, Hatfield AK, Edmonson JH, Blum RH, Stewart JA, Pandya KJ. Pain and its treatment in outpatients with metastatic cancer. N Engl J Med 1994, 330:592-596.
26. Ware JE, Sherbourne CD. The MOS 36-item short-form health survey (SF-36). I. Conceptual framework and item selection. Med Care 1992, 30:473-483.
27. Ware JE. SF-36 health survey update. Spine (Phila Pa 1976) 2000, 25:3130-3139.
28. Rabin R, de Charro F. EQ-5D: a measure of health status from the EuroQol Group. Ann Med 2001, 33:337-343.
29. Atkinson MJ, Sinha A, Hass SL, Colman SS, Kumar RN, Brod M, Rowland CR. Validation of a general measure of treatment satisfaction, the Treatment Satisfaction Questionnaire for Medication (TSQM), using a national panel study of chronic disease. Health Qual Life Outcomes 2004, 2:12. 12.
30. World Medical Association Declaration of Helsinki (October 2008). 2008, http://www.wma.net/en/30publications/10policies/b3/17c.pdf (Accessed 22nd July 2014), World Medical Association.
31. Department of Health Research governance framework for health and social care. 2005, https://www.gov.uk/government/uploads/system/uploads/attachment_data/file/139565/dh_4122427.pdf (Accessed 22nd July 2014), Department of Health.
32. SF-36 v2 US Population Norms. 1998, http://www.sf-36.org/research/sf98norms.pdf (Accessed 22nd July 2014).
33. Kind P, Hardman G, Macran S. UK Population Norms for EQ-5D 1999, United Kingdom: Centre for Health Economics, University of York, Working Papers.
34. Guyatt GH, Osoba D, Wu AW, Wyrwich KW, Norman GR, . Clinical Significance Consensus Meeting Group Methods to Explain the Clinical Significance of Health Status Measures. Mayo Clin Proc 2002, 77:371-383. Clinical Significance Consensus Meeting Group.
35. Sloan JA, Cella D, Hays RD. Clinical significance of patient-reported questionnaire data: another step toward consensus. J Clin Epidemiol 2005, 58:1217-1219.
36. Wyrwich KW, Tierney WM, Wolinsky FD. Further Evidence Supporting an SEM-Based Criterion for Identifying Meaningful Intra-Individual Changes in Health-Related Quality of Life. J Clin Epidemiol 1999, 52(9):861-873.
37. Hope-Simpson RE. The Nature of Herpes Zoster: A Long-term Study and a New Hypothesis. Proc R Soc Med 1965, 58:9-20.
38. Volpi A, Gatti A, Serafini G, Costa B, Suligoi B, Pica F, Marsella LT, Sabato E, Sabato AF. Clinical and psychosocial correlates of acute pain in herpes zoster. J Clin Virol 2007, 38:275-279.
39. Hurley RW, Adams MCB. Sex, Gender, and Pain: An Overview of a Complex Field. Anesth Analg 2008, 107:309-317.
40. Beutner KR, Friedman DJ, Forszpaniak C, Andersen PL, Wood MJ. Valaciclovir compared with acyclovir for improved therapy for herpes zoster in immunocompetent adults. Antimicrob Agents Chemother 1995, 39:1546-1553.
41. Tyring SK, Beutner KR, Tucker BA, Anderson WC, Crooks RJ. Antiviral Therapy for Herpes Zoster: Randomized, Controlled Clinical Trial of Valacyclovir and Famciclovir Therapy in Immunocompetent Patients 50 Years and Older. Arch Fam Med 2000, 9:863-869.
42. Wood MJ, Johnson RW, McKendrick MW, Taylor J, Mandal BK, Crooks J. A Randomized Trial of Acyclovir for 7 Days or 21 Days with and without Prednisolone for Treatment of Acute Herpes Zoster. N Engl J Med 1994, 330:896-900.
43. Jones KR, Vojir CP, Hutt E, Fink R. Determining mild, moderate, and severe pain equivalency across pain-intensity tools in nursing home residents. J Rehabil Res Dev 2007, 44:305-314.
44. Yawn BP, Wollan PC, Kurland MJ, St Sauver JL, Saddier P. Herpes Zoster Recurrences More Frequent Than Previously Reported. Mayo Clin Proc 2011, 86:88-93.
45. Serlin RC, Mendoza TR, Nakamura Y, Edwards KR, Cleeland CS. When is cancer pain mild, moderate or severe? Grading pain severity by its interference with function. Pain 1995, 61:277-284.
46. Mantyselka P, Kumpusalo E, Ahonen R, Takala J. Patients versus general practitioners assessments of pain intensity in primary care patients with non-cancer pain. Br J Gen Pract 2001, 51(473):995-997.
47. Department of Health Equity and Excellence: Liberating the NHS 2010, London: DH, Department of Health.
48. Carroll S, Gater A, Abetz-Webb L, Smith F, Demuth D, Mannan A. Challenges in quantifying the patient-reported burden of herpes zoster and post-herpetic neuralgia in the UK: learnings from the Zoster Quality of Life (ZQOL) study. BMC Res Notes 2013, 6:486.
49. Department of Health A new value-based approach to the pricing of branded medicines - a consultation. 2010, Available at http://www.dhsspsni.gov.uk/medicineconsultation.pdf (Accessed 22nd July 2014), Department of Health.
50. Harpaz R, Yawn BP. Trends in rates of herpes zoster-related hospitalizations: are they real, are they costly, and are they linked to varicella vaccination?. Infect Control Hosp Epidemiol 2009, 30:495-496.
51. Edmunds WJ, Brisson M, Rose JD. The epidemiology of herpes zoster and potential cost-effectiveness of vaccination in England and Wales. Vaccine 2001, 19:3076-3090.
52. Dworkin RH, Johnson RW, Breuer J, Gnann JW, Levin MJ, Backonja M, Betts RF, Gershon AA, Haanpää ML, McKendrick MW, Nurmikko TJ, Oaklander AL, Oxman MN, Langston DP, Petersen KL, Rowbotham MC, Schmader KE, Stacey BR, Tyring SK, van Wijck AJM, Wallace MS, Wassilew SW, Whitley RJ. Recommendations for the management of herpes zoster. Clin Infect Dis 2007, 44(Suppl 1):S1-S26.
53. World Health Organisation Integrating prevention into healthcare. 2002, http://www.scribd.com/immaniacs/d/32316439-WHO-Factsheet (Accessed 22nd July 2014), World Health Organisation.
54. NHS eQIPP: a comprehensie online resource to help you identify opportunities and support quality improvement in NHS services. 2012, https://www.evidence.nhs.uk/qipp (Accessed 22nd July 2014), NHS.
55. Oxman MN, Levin MJ, Johnson GR, Schmader KE, Straus SE, Gelb LD, Arbeit RD, Simberkoff MS, Gershon AA, Davis LE, Weinberg A, Boardman KD, Williams HM, Zhang JH, Peduzzi PN, Beisel CE, Morrison VA, Guatelli JC, Brooks PA, Kauffman CA, Pachucki CT, Neuzil KM, Betts RF, Wright PF, Griffin MR, Brunell P, Soto NE, Marques AR, Keay SK, Goodman RP, et al. A vaccine to prevent herpes zoster and postherpetic neuralgia in older adults. N Engl J Med 2005, 352:2271-2284.